USANA Health Sciences (NYSE:USNA) Issues FY 2025 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 2.350-3.000 for the period, compared to the consensus EPS estimate of 2.610. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $947.0 million.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock traded up $1.42 on Tuesday, reaching $31.71. 153,108 shares of the stock were exchanged, compared to its average volume of 142,042. The firm's 50 day moving average is $30.64 and its 200-day moving average is $30.12. USANA Health Sciences has a one year low of $23.10 and a one year high of $46.44. The firm has a market cap of $590.44 million, a PE ratio of 17.42, a P/E/G ratio of 0.97 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.98% and a return on equity of 8.94%. On average, equities research analysts expect that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Insider Transactions at USANA Health Sciences

In related news, CFO G Doug Iiekking sold 4,548 shares of the business's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $29.61, for a total transaction of $134,666.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Walter Noot sold 6,291 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total transaction of $190,554.39. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock valued at $360,149 over the last quarter. Corporate insiders own 0.63% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in USANA Health Sciences stock. AQR Capital Management LLC grew its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 82.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,845 shares of the company's stock after acquiring an additional 9,894 shares during the quarter. AQR Capital Management LLC owned about 0.12% of USANA Health Sciences worth $589,000 at the end of the most recent quarter. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.